Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia
- 4 March 2010
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 115 (9), 1697-1702
- https://doi.org/10.1182/blood-2009-07-230805
Abstract
The aim of this study was to determine the efficacy and safety of treatment of pediatric acute promyelocytic leukemia (APL) with single-agent arsenic trioxide (ATO). A total of 19 children (≤ 15 years of age) with newly diagnosed APL were treated with single-agent ATO for remission induction and postremission therapy. Seventeen of the children (89.5%) achieved complete hematologic remission, and 2 early deaths occurred from intracranial hemorrhage. ATO-induced leukocytosis was observed in 13 (68.4%) patients. Other ATO-related toxicities were minimal and transient. Postremission ATO therapy continued for 3 years; the most common side effect was ATO-induced neutropenia. With a median follow-up of 53 months (range, 23-76 months), the calculated 5-year overall survival and event-free survival were 83.9% and 72.7%, respectively, which are comparable with results achieved by the use of ATRA plus chemotherapy, which is the standard therapy for APL. No chronic arsenic toxicity or second malignancies were found during the follow-up period, and arsenic retention was not significant in patients off treatment more than 24 months. ATO resistance was observed in only 1 patient with a complex karyotype. The results indicate the high efficacy and safety of single-agent ATO regimens in the treatment of children with de novo APL.Keywords
This publication has 18 references indexed in Scilit:
- Acute promyelocytic leukemia: from highly fatal to highly curableBlood, 2008
- Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicityBlood, 2006
- Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA GroupJournal of Clinical Oncology, 2005
- GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in childrenPublished by American Society of Hematology ,2005
- Outcome of Childhood Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid and ChemotherapyJournal of Clinical Oncology, 2004
- Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA groupBlood, 2003
- Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemiaMedical and Pediatric Oncology, 2003
- Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experienceAmerican Journal of Hematology, 2002
- Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in childrenAnnals of Hematology, 2001
- Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer.Journal of Clinical Oncology, 1992